Study Dashes Hopes That Tremelimumab May Extend Survival Rates

A report published in The Lancet Oncology had sobering news for the drug Tremelimumab, a drug that had produced high hopes that it could extend survival rates for those diagnosed with mesothelioma. The study examined the international clinical trial with over 500 patients to see whether AstraZeneca’s drug could in fact extend average survival rates. The clinical trial started in 2013.

The double-blind trial was conducted at 105 sites in 19 different countries. The patients had either pleural or peritoneal mesothelioma. Over a period of seven months some patients were administered Tremelimumab while others, who were selected at random, were given a placebo. Neither the doctors nor the patients knew who was given the drug versus the placebo.

The report concluded that “Tremelimumab did not significantly prolong overall survival compared with the placebo in patients with previously treated malignant mesothelioma.” While the results of the study were disappointing there is still hope that the when used in combination with other medications that Tremelimumab will be able to increase the efficacy other drugs.

The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.

Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers